Wedbush Rates Cullinan Therapeutics (CGEM) buy, $37 Price Target

Wedbush kept its buy rating for Cullinan Therapeutics, targeting $37 as of June 11, 2026, a 171.86% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 16, 2026, 2:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wedbush rated Cullinan Therapeutics, Inc. ($CGEM) "buy" with a $37 price target on June 11, 2026.

Since the rating, $CGEM is up 15.8% after 1 week, up 37.7% after 1 month and down 0.4% to date (from the $12.98 close on Jun 11, 2026).

CGEM Cullinan Therapeutics, Inc.

$12.93 +27.77% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Wedbush reiterated its buy rating on Cullinan Therapeutics, Inc. (CGEM), with a target price of $37.00.
Wedbush's $37 price target implies 171.86% upside from Cullinan Therapeutics, Inc.'s ($CGEM) current $13.61 share price.
The stock is currently priced at $13.61, significantly lower than the target price set by Wedbush, indicating potential for growth.
Cullinan Therapeutics operates in the biotechnology sector, focusing on therapies for cancer and autoimmune diseases.

Get $CGEM trade alerts by text

We text you when insiders, Congress or big funds trade $CGEM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cullinan Therapeutics, Inc. alert may contain errors. Disclosures

Analysts Set New Price Targets

On June 11, 2026, Wedbush reiterated its buy rating for Cullinan Therapeutics, Inc. (CGEM) with a price target of $37.00. The stock is currently trading at $13.61, suggesting a substantial upside based on the analyst's valuation.

Analysts Set New Price Targets

Wedbush's rating comes at a time when other analysts are also expressing positive views on Cullinan Therapeutics. Notably, HC Wainwright & Co. has maintained a buy rating with a target price of $35.00, which it reiterated on October 2, 2026. Prior to that, HC Wainwright raised its target from $30.00 on September 25, 2026. Additionally, BTIG has consistently rated the stock as a buy, most recently maintaining a target of $40.00 on September 25, 2026, after previously raising it from $39.00. This collective outlook suggests strong confidence in the company's future prospects.

Stock Performance Highlights

As of the publication date, Cullinan Therapeutics is trading significantly below its 52-week high of $23.19. The stock has experienced considerable volatility but remains well above its 52-week low of $5.68. The current trading price near $13.61 provides room for growth, especially in light of the optimistic ratings from analysts.

12-month forecast

$CGEM price target

Cullinan Therapeutics, Inc. daily closes and this analyst's $37 target. Not advice.

What Cullinan Therapeutics, Inc. Does

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It specializes in developing therapies aimed at treating autoimmune diseases and certain types of cancer. With ongoing clinical trials for various bispecific T cell engagers, the company is positioned to make a significant impact in the healthcare sector.

What’s Next for Cullinan?

Investors will be watching closely for Cullinan Therapeutics' next earnings report, scheduled for November 14, 2026. The 13F filings that reflect past positions may not represent current holdings, but the bullish sentiment from Wedbush and other analysts signals potential moves ahead for the stock. As the company continues its clinical trials and develops its product pipeline, market reactions will be crucial to watch.